Boston conference will explore strategic partnering, device innovation, and delivery solutions for emerging therapeutics.

Farwell succeeds Jordan Dubow, who will continue to serve as a consultant and chair of the Clinical Advisory Board.

Illimis Therapeutics’ Series B round was led by Korean venture capital firm DSC Investment. Seoul-based Illimis Therapeutics has raised 58 billion won ($42 million) to fund its research into ...

BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that the drug discovery research for lecanemab (product name Leqembi®), an antibody indicated for early Alzheimer's ...

The Bioindustry Award, now marking its 9th year, recognizes achievements that have significantly contributed to the development of the bioindustry or are expected to contribute to its future growth.

This was the stock's third consecutive day of losses.

UBS analyst Ashwani Verma maintained a Hold rating on Biogen today and set a price target of $130.00. The company’s shares opened today at $133.56. Elevate Your Investing Strate ...